Q4 and Full Year 2025 Earnings Presentation March 10, 2026 © 2026 Esperion Therapeutics, Inc. All rights reserved. Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization and business development plans, current and planned operational expenses, expected profitability, future operations, commercial products ...

Core Insights - Erasca, Inc. has expanded its license agreement with Joyo Pharmatech to secure worldwide rights for ERAS-0015, a promising pan-RAS molecular glue targeting RAS/MAPK pathway-driven cancers [1][2][3] - Initial Phase 1 monotherapy data for ERAS-0015 is expected in the first half of 2026, with early clinical activity showing potential across multiple tumor types and RAS mutations [3][4] Company Overview - Erasca is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, co-founded by pioneers in precision oncology [5] - The company aims to comprehensively inhibit the RAS/MAPK pathway to treat cancer patients, leveraging expertise from its scientific advisory board [5] Product Details - ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling, demonstrating favorable safety and tolerability in early trials [4] - In preclinical studies, ERAS-0015 showed 8-21 times higher binding affinity to cyclophilin A compared to RMC-6236 and approximately 5 times greater potency in RAS inhibition [4]

Core Viewpoint - LENZ Therapeutics has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for VIZZ, an aceclidine ophthalmic solution, marking a significant step in expanding global access to this treatment for presbyopia [1][3] Group 1: Regulatory Submission and Milestones - The MAA submission to the EMA represents the fifth regulatory submission for VIZZ outside the U.S. [1] - If approved, VIZZ will be available to millions of Europeans suffering from age-related blurry near vision [1][3] - The submission is part of LENZ's strategy to establish VIZZ as a global brand, with ongoing commercialization efforts in various regions including Greater China, South Korea, and the Middle East [3] Group 2: Clinical Data and Efficacy - The MAA is supported by positive results from three Phase 3 CLARITY trials conducted in the U.S., where VIZZ met all primary and secondary endpoints, improving near vision within 30 minutes and lasting up to 10 hours [2] - VIZZ was well tolerated, with no serious treatment-related adverse events reported over 30,000 treatment days across the trials [2] Group 3: Market Opportunity and Company Strategy - Presbyopia affects approximately 1.8 billion people globally, with Europe being a significant market for vision correction products [3] - The company aims to pursue commercialization in Europe through strategic partnerships, complementing existing partnerships in other regions [3][4]

Core Insights - BioNTech, initially focused on cancer, gained prominence during the COVID-19 pandemic by partnering with Pfizer to develop the first COVID-19 vaccine, Comirnaty, which peaked in sales at nearly $38 billion in 2022 [3][4] - Following the decline in vaccine sales as the pandemic subsided, BioNTech is refocusing on cancer treatments, investing heavily in a pipeline that includes vaccines, bispecific antibodies, and cell therapies [5] - The company is set to have 15 Phase 3 trials in cancer by the end of the year and anticipates multiple late-stage data readouts across major cancer types [6] Company Transition - Co-founders Ugur Sahin and Özlem Türeci will leave BioNTech by the end of the year to establish a new startup focused on next-generation mRNA innovations, with BioNTech granting certain rights to its mRNA technology in exchange for a minority stake [6] - BioNTech will concentrate on advancing its late-stage cancer medicine portfolio and is in the process of searching for successors to ensure a smooth transition [6] - Further details regarding the partnership with the new startup will be provided once an official deal is signed, expected to be completed by the end of the first half of the year [6]

Core Viewpoint - Orion Corporation has transferred 172,778 of its own B shares as part of a share reward for the earning period 2023–2025, in accordance with the Share-based Incentive Plan [1][2] Group 1: Share Transfer Details - The transfer of shares was authorized by the Annual General Meeting held on 23 March 2022 [2] - After the transfer, Orion Corporation holds a total of 268,166 own B shares [2] Group 2: Company Overview - Orion Pharma is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [2] - The company reported net sales of EUR 1,890 million in 2025 and employs approximately 4,000 professionals globally [2] - Core therapy areas for Orion's pharmaceutical R&D include oncology and pain management, with proprietary products aimed at treating cancer, respiratory diseases, and neurological diseases [2]

Core Insights - Eli Lilly and Company is preparing to launch its new oral obesity drug, orforglipron, in the United States as early as Q2 2023, pending FDA approval [1][2] - The company has $1.5 billion worth of pre-launch inventory ready for distribution shortly after receiving FDA approval [2] - Eli Lilly has also launched the Employer Connect platform to enhance access to obesity care for employees, facilitating coordination between employers and program administrators [3] Group 1 - Eli Lilly's CFO stated that the FDA review is progressing as expected, and the company remains confident in a decision by Q2 [2] - The company can begin shipping the obesity drug within about a week after FDA approval, enabling a rapid market rollout [2] - The Employer Connect platform aims to close the access gap in U.S. obesity care by providing flexible solutions for employee access to obesity management medications [3] Group 2 - Eli Lilly develops and sells pharmaceutical products across various therapeutic areas, including oncology, diabetes, immunology, and neuroscience [4]

Core Insights - Johnson & Johnson (NYSE: JNJ) is involved in a $65 million antitrust class action settlement related to its pulmonary hypertension drug Tracleer, which allegedly delayed competition for a generic version of the medication [2] - The company operates through two main segments: Innovative Medicine, focusing on therapeutic areas such as oncology and immunology, and MedTech, which includes a wide range of medical devices [3] Group 1 - Johnson & Johnson units have agreed to pay $65 million to settle claims from health plans alleging overcharging for Tracleer [2] - The lawsuit claimed that Johnson & Johnson obstructed competitor access to Tracleer samples, hindering the market entry of generic alternatives [2] - Actelion Pharmaceuticals, which developed Tracleer and was acquired by Johnson & Johnson in 2017, reportedly made billions in profits from the drug [2] Group 2 - The Innovative Medicine segment of Johnson & Johnson focuses on various therapeutic areas, including oncology, infectious diseases, and cardiovascular diseases [3] - The MedTech segment encompasses a diverse range of medical devices used in fields such as cardiovascular intervention and orthopedics [3]

Core Viewpoint - The recent partnership with Novo Nordisk has alleviated significant legal risks for Hims & Hers Health, leading to a sharp rebound in its stock price and opening up new market opportunities for the company [1][3][10]. Group 1: Legal and Market Developments - The lawsuit from Novo Nordisk, which posed a major threat to Hims due to its compounded semaglutide products, has been dropped, allowing Hims to offer branded treatments like Ozempic and Wegovy [1][2][3]. - Hims' stock has increased by 40% in a single day, trading above $22, reflecting investor optimism about the company's growth potential [2][3]. Group 2: Financial Performance - Hims reported a revenue of $2.35 billion for 2025, marking a 59% year-over-year increase, with a net income of $128 million [5]. Group 3: Expansion Strategies - The company is pursuing international expansion by acquiring Eucalyptus, a digital health platform, which will enhance its ability to distribute weight-loss therapies across various international markets [6]. - Hims could become a key distribution partner for multiple GLP-1 manufacturers, positioning itself as a significant player in the digital health space for metabolic drugs [7]. Group 4: Future Outlook - The success of Hims will depend on its ability to scale its subscriber platform, secure additional drug partnerships, and maintain its growth trajectory [10]. - Investor sentiment remains positive, driven by strong revenue growth and expanded access to blockbuster treatments, suggesting that Hims shares are worth monitoring in the near future [11].

Corporate Presentation March 2026 Forward-Looking Statements Disclaimers Except for historical information, all of the statements, expectations and assumptions contained in this presentation are forward-looking statements. These forward-looking statements may include information concerning possible or projected future business operations. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ mater ...

Core Insights - Tenax Therapeutics has achieved its randomization target of 230 patients in the Phase 3 LEVEL study, with topline data expected in the third quarter of 2026 [2][6] - The company has initiated the global Phase 3 LEVEL-2 clinical trial and opened a long-term open-label extension study for patients to continue receiving the drug [1][2] Recent Corporate and Clinical Highlights - The screening period for the LEVEL study has closed, and randomization is anticipated to be completed by the end of March 2026 [2][6] - Tenax is focused on activating clinical sites globally for the LEVEL-2 study, which is expected to complete enrollment by the end of 2027 [2][6] - A virtual call with key opinion leaders was held in November 2025 to discuss the treatment landscape for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) [6] - In December 2025, a prespecified Blinded Sample Size Re-estimation (BSSR) demonstrated that the LEVEL study is powered at over 90% to detect a 25-meter change in 6-minute walk distance [6] Financial Results - As of December 31, 2025, Tenax reported cash and cash equivalents of $97.6 million, expected to fund operations through 2027 [4] - Research and development (R&D) expenses for Q4 2025 were $10.5 million, up from $4.6 million in Q4 2024, with total R&D expenses for the year at $32.7 million compared to $12.7 million in 2024 [5][7] - General and administrative (G&A) expenses for Q4 2025 were $5.9 million, compared to $2.7 million in Q4 2024, with total G&A expenses for the year at $23.7 million versus $6.8 million in 2024 [8] - The net loss for Q4 2025 was $15.5 million, compared to a net loss of $6.3 million in Q4 2024, with a total net loss for the year of $52.6 million compared to $17.6 million in 2024 [9][18]